Ginsenoside Rp1 from Panax ginseng Exhibits Anti-cancer Activity by Down-regulation of the IGF-1R/Akt Pathway in Breast Cancer Cells

Plant Foods for Human Nutrition

Volumn 66, Issue 3, 2011, Pages 298-305

  Kang, Ju Hee ^a,b   Song, Ki Hoon ^a   Woo, Jong Kyu ^c   Park, Myung Hwan ^d   Rhee, Man Hee ^e   Choi, Changsun ^b   Oh, Seung Hyun ^a  

^a National Cancer Center   (South Korea)

^b Chung Ang University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Ambo Institute   (South Korea)

^e Kyungpook National University   (South Korea)

Author keywords

Akt; Breast cancer; Ginseng; Ginsenoside Rp1; IGF 1R

Indexed keywords

ANTINEOPLASTIC AGENT; GINSENOSIDE; GINSENOSIDE RP1; PLANT EXTRACT; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; PANAX; PHYTOTHERAPY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GINSENOSIDES; HUMANS; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1;

PANAX GINSENG;

EID: 80051787458     PISSN: 09219668     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11130-011-0242-4     Document Type: Article

References (32)

1. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71: 787-795.
2. Hortobagyi GN, Piccart-Gebhart MJ (1996) Current management of advanced breast cancer. Semin Oncol 23: 1-5.
3. Glade MJ (1999) Food, nutrition, and the prevention of cancer: A global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 15: 523-526.
4. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O (2010) Cancer prevention with natural compounds. Semin Oncol 37: 258-281.
5. Sen T, Dutta A, Chatterjee A (2010) Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs 21: 632-644.
6. Murillo G, Peng X, Torres KE, Mehta RG (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila) 2: 942-950.
7. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
8. Yun TK (2001) Brief introduction of Panax ginseng C. A. Meyer. J Korean Med Sci 16(Suppl): S3-S5.
9. Szeto YT, Wong JW, Wong SC, Pak SC, Benzie IF (2011) DNA protective effect of ginseng and the antagonistic effect of Chinese turnip: A preliminary study. Plant Foods Hum Nutr.
10. Cheung SC, Szeto YT, Benzie IF (2007) Antioxidant protection of edible oils. Plant Foods Hum Nutr 62: 39-42.
11. Kang KS, Yamabe N, Kim HY, Park JH, Yokozawa T (2010) Effects of heat-processed ginseng and its active component ginsenoside 20(S)-Rg3 on the progression of renal damage and dysfunction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty rats. Biol Pharm Bull 33: 1077-1081.
12. Helms S (2004) Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9: 259-274.
13. Li B, Wang CZ, He TC, Yuan CS, Du W (2010) Antioxidants potentiate American ginseng-induced killing of colorectal cancer cells. Cancer Lett 289: 62-70.
14. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W (2006) Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 163: 645-653.
15. Park TY, Park MH, Shin WC, Rhee MH, Seo DW, Cho JY, Kim HM (2008) Anti-metastatic potential of ginsenoside Rp1, a novel ginsenoside derivative. Biol Pharm Bull 31: 1802-1805.
16. Kumar A, Kumar M, Park TY, Park MH, Takemoto T, Terado T, Kitano M, Kimura H (2009) Molecular mechanisms of ginsenoside Rp1-mediated growth arrest and apoptosis. Int J Mol Med 24: 381-386.
17. Kim BH, Cho JY (2009) Regulatory role of ginsenoside Rp1, a novel ginsenoside derivative, on CD29-mediated cell adhesion. Planta Med 75: 316-320.
18. Kim BH, Lee YG, Park TY, Kim HB, Rhee MH, Cho JY (2009) Ginsenoside Rp1, a ginsenoside derivative, blocks lipopolysaccharide-induced interleukin-1beta production via suppression of the NF-kappaB pathway. Planta Med 75: 321-326.
19. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
20. Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90.
21. Chen H, Yan GC, Gishizky ML (1998) Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor 1 receptors. Cell Growth Differ 9: 939-947.
22. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
23. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588.
24. Cho JY, Yoo ES, Baik KU, Park MH, Han BH (2001) In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists. Planta Med 67: 213-218.
25. Kumar A, Kumar M, Panwar M, Samarth RM, Park TY, Park MH, Kimura H (2006) Evaluation of chemopreventive action of Ginsenoside Rp1. Biofactors 26: 29-43.
26. Baserga R (1995) The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55: 249-252.
27. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC (2001) Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 61: 1367-1374.
28. Luqman S, Pezzuto JM (2010) NFkappa B: A promising target for natural products in cancer chemoprevention. Phytother Res 24: 949-963.
29. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
30. Martins AS, Ordonez JL, Garcia-Sanchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gurpide J, de Alava E (2008) A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 68: 6260-6270.
31. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100: 1523-1529.
32. Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy. Biochem Pharmacol 60: 1101-1107.